RCKT · Rocket Pharmaceuticals, Inc.

Rocket’s Q1 2026 results reflect a strategic inflection point: the company transitioned from R&D investment to commercial execution with the March 2026 FDA accelerated approval of KRESLADI™, its first approved gene therapy for severe LAD-I. The $180 million non-dilutive monetization of the Rare Pediatric Disease Priority Review Voucher—completed April 28, 2026—directly bolsters liquidity, lifting pro forma cash to $322.6 million and extending the operational runway to Q2 2028. This capital preservation is reinforced by disciplined expense management: R&D spending declined 12.3% year-over-year to $31.5 million, driven by $5.8 million lower manufacturing and material costs and $2.0 million in reduced compensation, offset partially by higher clinical trial expenses. G&A expenses dropped 39.8% to $17.1 million, largely due to the absence of a $5.7 million legal settlement incurred in Q1 2025 and $4.6 million lower commercial preparation spend—consistent with delayed commercial launch timing pending payer engagement and infrastructure build-out. Net loss improved to $47.6 million ($0.42 per share), reflecting both cost discipline and the absence of prior-year one-time charges. Management’s commentary emphasizes continued focus on cardiovascular pipeline execution—particularly RP-A501’s pivotal Danon disease trial, now reinitiated under revised FDA-agreed dosing and immunomodulation—with a program update anticipated in H2 2026. The combination of regulatory milestone achievement, non-dilutive capital generation, and sustained cost control signals enhanced financial resilience and de-risks near-term execution across multiple late-stage programs.